BAL101553

DRUG2 trials

Sponsors

Basilea Pharmaceutica

Conditions

NeoplasmsSolid Organ Tumors

Phase 1

An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors

CompletedNCT01397929

Basilea PharmaceuticaSolid Organ Tumors

Start: 2011-06-30End: 2016-04-30Updated: 2023-05-10

Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma

CompletedNCT02895360

Basilea PharmaceuticaNeoplasms

Start: 2016-08-24End: 2020-08-07Updated: 2023-05-10

Related Papers

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study

Investigational New Drugs2023-02-166 citations

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.

2020-08-038 citations

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Investigational New Drugs2019-08-3012 citations

Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-201 citations

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-20

Phase 1/2a trial of daily oral BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.

Journal of Clinical Oncology2017-05-201 citations

A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.

Journal of Clinical Oncology2017-05-201 citations

A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-20

Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.

Journal of Clinical Oncology2016-05-203 citations

A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.

Journal of Clinical Oncology2015-05-20

Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.

Journal of Clinical Oncology2014-05-201 citations